T1DM Pathological Research Service

T1DM Pathological Research Service

Through pathological research, we can better understand the mechanisms, development rules of T1DM, and metabolism in the process of diseases, which is helpful for the development of therapies. Ace Therapeutics provides pathological research programs and materials for research T1DM, mainly including animal models and other experimental materials.

Pathogenesis of T1DM

The studies have demonstrated that the disease occurs as a consequence of a breakdown in immune regulation, resulting in the expansion of autoreactive CD4+ and CD8+ T cells, autoantibody-producing B lymphocytes, and activation of the innate immune system that collaborate to destroy the insulin-producing β-cells. It is estimated that about 40-50% of the risk of T1DM is related to major histocompatibility complex (MHC) complex or IDDM1 locus.

Genetic Susceptibility Locus

Non-obese diabetes (NOD) mouse, as the main animal model of T1DM, have many aspects in common with the human disease, including a number of similarities in genetic loci of susceptibility, influence of the environment and pathogenesis of disease. There are now at least 26 known genetic susceptibility loci for T1DM. The most important are IDDM1, IDDM2, PTPN22, et al.

IDDM1 IDDM1 is located at 6p21 of human chromosome, which contains HLA genes.
IDDM2 This gene is located on human chromosome 11p15 and contains the insulin gene.
PTPN22 PTPN22 is protein tyrosine phosphatase gene, which has mutations on LYP (lymphocyte specific phosphatase gene) on chromosome 1.
IDDM12 the IDDM12 locus contains some genes that may cause diabetes. The CTLA4, CD28 and ICOS can inhibit some functions of T cells.

Our Services

With years of experience in translational medicine research and drug development, Ace Therapeutics is able to provide research services to study the genes, biochemical pathways, modules and their action networks related to diabetes at the molecular and cellular levels, and carry out integration and systematic analysis. Our services include but not limited to the followings.

  • Regulator Gene Identification
    Discovering new pathogenic genes and mutant types of known pathogenic gene related to T1DM.
  • Epigenetic Regulator Discovery
    Exploring important molecules, pathways and regulatory networks related to epigenetic modification and development.
  • Effectiveness Evaluation Service
    Including the effectiveness evaluation of immunological testing, physiological and biochemical testing, behavioral testing, cell function testing, molecular biology testing and other diabetes phenotype analysis.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualityHigh Quality

Professional TeamProfessional Team

Ace Therapeutics offers cost-effect and high-quality research services related to T1DM for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.


  1. Wei, J.; et al. The Influence of Different Types of Diabetes on Vascular Complications. Journal of Diabetes Research. 2022.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.